
The Unfolding Transformation of Big Pharma: The Rise of China
Major American pharmaceutical companies are increasingly partnering with Chinese firms, with nearly 30% of large pharma deals in 2024 involving Chinese entities. Chinese advancements in developing cost-effective molecules and rapid trial capabilities attract U.S. companies seeking new breakthroughs. As the U.S. emphasizes